Program
Temozolomide
Also written as “temozolomide”, “Temozolomide (TMZ)” and “TMZ”.
Its studies are mostly in Glioblastoma · Glioma · Sarcoma, Ewing · Melanoma · Carcinoma, Non-Small-Cell Lung, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 150 open or running | phase 4since May 27, 2008 | May 1, 2002 | none ahead |
| Eli Lilly | 42 open or running | phase 2since Oct 12, 2010 | Oct 12, 2010 | May 2027phase 2 · NCT05999994 |
| Hoffmann-La Roche | 20 open or running | phase 2since Apr 30, 2010 | Apr 30, 2010 | none ahead |
| Leaf Vertical | 20 open or running | phase 2since Jun 5, 2018 | Jun 5, 2018 | none ahead |
| Orphelia Pharma | 20 open or running | phase 1since Mar 27, 2020 | Mar 27, 2020 | none ahead |
| SynerGene Therapeutics | 20 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since Sep 7, 2016 | Sep 7, 2016 | none ahead |
| CASI Pharmaceuticals | 10 open or running | phase 2since May 30, 2007 | May 30, 2007 | none ahead |
| monte-verde-sa | 10 open or running | phase 4since Jan 7, 2015 | Jan 7, 2015 | none ahead |
| monteris-medical | 10 open or running | phase 1since Aug 18, 2016 | Aug 18, 2016 | none ahead |
| NovoCure | 10 open or running | no phasesince Dec 18, 2018 | Dec 18, 2018 | none ahead |
| vion-pharmaceuticals | 10 open or running | phase 1since Dec 7, 2004 | Dec 7, 2004 | none ahead |
| zsky-biotech-inc | 11 open or running | phase 2since Jan 5, 2026 | Jan 5, 2026 | Dec 24, 2028phase 2 · NCT07365280 |
Also a collaborator on its studies: triphase-research-and-development-iii-corp, aesca-pharma-gmbh and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since May 1, 2002.
- Dec 18, 2014SynerGene Therapeutics's first study: phase 2 study in GlioblastomaNew to SynerGene TherapeuticsSynerGene Therapeutics · NCT02340156 · 1 enrolled · United States, Taiwan
- Jan 7, 2015monte-verde-sa's first study: phase 4 study in Brain NeoplasmsNew to monte-verde-samonte-verde-sa · NCT02343081 · 24 enrolled · Argentina
- Aug 18, 2016monteris-medical's first study: phase 1 study in GlioblastomaNew to monteris-medicalmonteris-medical · NCT02880410 · 3 enrolled · United States
- Sep 7, 2016Bristol-Myers Squibb's first study: phase 1 study in GlioblastomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02903069 · 66 enrolled · United States, Canada, Switzerland
- May 17, 2018Early phase 1 study in Central Nervous System NeoplasmsSynerGene Therapeutics · NCT03554707 · United States
- Jun 5, 2018Leaf Vertical's first study: phase 2 study in Pancreatic NeoplasmsNew to Leaf VerticalLeaf Vertical · NCT03607643 · 160 enrolled · United States
- Aug 22, 2018Phase 1 study in GlioblastomaLeaf Vertical · NCT03687034 · 21 enrolled
- Dec 18, 2018NovoCure's first study: no phase study in GlioblastomaNew to NovoCureNovoCure · NCT03780569 · 10 enrolled · Israel
- Jan 22, 2020Phase 2 study in Sarcoma, EwingEli Lilly · NCT04238819 · 47 enrolled · United States, Australia, Belgium and more
- Mar 27, 2020Orphelia Pharma's first study: phase 1 study in Therapeutic EquivalencyNew to Orphelia PharmaOrphelia Pharma · NCT04467346 · 36 enrolled · France
- Oct 20, 2020Phase 1 study in NeoplasmsOrphelia Pharma · NCT04610736 · 49 enrolled · France, Germany, Netherlands and more
- Jun 28, 2022Phase 2 study in Sarcoma, EwingEli Lilly · NCT05440786 · 46 enrolled · United States, Australia, France and more
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- Jan 5, 2026zsky-biotech-inc's first study: phase 2 study in GlioblastomaNew to zsky-biotech-inczsky-biotech-inc · NCT07365280 · 78 planned
Ahead
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
- Dec 24, 2028Primary completion: phase 2 study in Glioblastomazsky-biotech-inc · NCT07365280
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07365280Glioblastoma | 2 | Not yet recruiting | zsky-biotech-inc | Dec 24, 2028 | 78 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05440786Sarcoma, Ewing · United States, Australia, France and more | 2 | Active, not recruiting | Eli Lilly | Jan 15, 2025 | 46 |
| NCT04610736Neoplasms · France, Germany, Netherlands and more | 1 | Completed | Orphelia Pharma | Jan 15, 2023 | 49 |
| NCT04467346Therapeutic Equivalency · France | 1 | Completed | Orphelia Pharma | Dec 17, 2021 | 36 |
| NCT04238819Sarcoma, Ewing · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Mar 15, 2024 | 47 |
| NCT03780569Glioblastoma · Israel | – | UNKNOWN | NovoCure | Jan 2019 | 10 |
| NCT03687034Glioblastoma | 1 | UNKNOWN | Leaf Vertical | Sep 30, 2019 | 21 |
| NCT03607643Pancreatic Neoplasms · United States | 2 | UNKNOWN | Leaf Vertical | Jun 30, 2020 | 160 |
| NCT03554707Central Nervous System Neoplasms · United States | Early 1 | Withdrawn | SynerGene Therapeutics | Jun 1, 2022 | 0 |
| NCT02903069Glioblastoma · United States, Canada, Switzerland | 1 | Completed | Bristol-Myers Squibb | Jan 25, 2021 | 66 |
| NCT02880410Glioblastoma · United States | 1 | Terminated | monteris-medical | Sep 14, 2018 | 3 |
| NCT02343081Brain Neoplasms · Argentina | 4 | Completed | monte-verde-sa | Oct 2013 | 24 |
| NCT02340156Glioblastoma · United States, Taiwan | 2 | Terminated | SynerGene Therapeutics | Nov 2018 | 1 |
| NCT01860638Glioblastoma · Austria, Bulgaria, Canada and more | 2 | Completed | Hoffmann-La Roche | Jan 13, 2017 | 296 |
| NCT01220271Glioma · United States, Germany, Spain | 2 | Completed | Eli Lilly | Aug 2015 | 75 |
| NCT01115491Glioblastoma · Spain | 2 | Completed | Hoffmann-La Roche | Jul 2012 | 32 |
| NCT00831545Melanoma | 2 | Completed | Merck | Oct 20, 2006 | 162 |
| NCT00783393Astrocytoma | 2 | Completed | Merck | Jun 17, 2005 | 32 |
| NCT00687323Leukemia, Myeloid, Acute | 2 | Completed | Merck | May 9, 2011 | 47 |
| NCT00686725Glioblastoma | 4 | Completed | Merck | Sep 28, 2011 | 99 |
| NCT00684567Glioblastoma | 2 | Completed | Merck | Oct 31, 2007 | 30 |
| NCT00632203Carcinoma, Non-Small-Cell Lung | 2 | Terminated | Merck | Jan 6, 2011 | 53 |
| NCT00638963Breast Neoplasms | 2 | Terminated | Merck | Jun 30, 2010 | 6 |
| NCT00481455Glioblastoma · United States | 2 | Completed | CASI Pharmaceuticals | Sep 2007 | 15 |
| NCT00424554Glioma | 2 | Completed | Merck | Jan 11, 2010 | 40 |
| NCT00423150Colorectal Neoplasms | 2 | Terminated | Merck | Jun 11, 2009 | 86 |
| NCT00392171Glioma | 2 | Completed | Merck | Sep 15, 2009 | 120 |
| NCT00335075Glioblastoma | 3 | Completed | Merck | Feb 23, 2006 | 151 |
| NCT00266812Carcinoma, Non-Small-Cell Lung | 2 | Terminated | Merck | Jan 16, 2008 | 35 |
| NCT00098436Leukemia · United States | 1 | Completed | vion-pharmaceuticals | Oct 2006 | 25 |
| NCT00091572Melanoma | 3 | Completed | Merck | Dec 31, 2007 | 859 |
| NCT00076856Carcinoma, Non-Small-Cell Lung | 2 | Completed | Merck | Mar 31, 2006 | 95 |
| NCT00034697Neoplasm Metastasis | 2 | Terminated | Merck | Jan 30, 2003 | 24 |
How it is read
Names in the registry
- “Temozolomide”, 37 entries
- “temozolomide”, 11 entries
- “Temozolomide (TMZ)”, 3 entries
- “TMZ”, 2 entries
- “Olutasidenib + TMZ”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 27 studies
- Glioma, 7 studies
- Sarcoma, Ewing, 5 studies
- Melanoma, 4 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.